LAVAL, QC en CAMBRIDGE, Engeland, 6 april 2023 /PRNewswire/ — Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” of de “Onderneming”), bevestigt dat de Raad van Bestuur van de Onderneming (de “Raad”) na sluiting van de markten op 4 april 2023 een niet-bindend voorstel heeft…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.